⚡ Interrogation des APIs scientifiques en cours…
⚡ Interrogation des APIs scientifiques en cours…
Authors' conclusion
Does not affect the score
Publi-Score
Fidelity
Abstract (PubMed)
Retrospective cohort study using EHR of 113 million US patients. N=1,651,452 T2D patients, GLP-1RAs vs insulins or metformin (2005-2018). GLP-1RAs vs insulin: significant risk reduction in 10 of 13 OACs including gallbladder cancer (HR 0.35), meningioma (HR 0.37), pancreatic cancer (HR 0.41). GLP-1RAs vs metformin: mostly non-significant. Erratum published June 2025.
Coeff. authors = avg(1.00, 1.00) = 1.00
Coeff. editorial = avg(0.80, 0.90) = 0.85
min(1.00, 0.85) = 0.85← lowest dominates
Final coefficient : 0.85
Final score = 37.4/52.8 × 0.85 × 100 = 60/100
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review a…
Wang DY — 2018 · JAMA Oncology
GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity
Dai H — 2025 · JAMA Oncology
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso SP — 2016 · The New England Journal of Medicine
Tumor Mutational Burden and Response Rate to PD-1 Inhibition.
Yarchoan M — 2017 · The New England journal of medicine
Effect of daily aspirin on long-term risk of death due to cancer: analysis of individua…
Rothwell PM — 2011 · Lancet (London, England)